283 related articles for article (PubMed ID: 8797767)
1. Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101.
Sredni B; Tichler T; Shani A; Catane R; Kaufman B; Strassmann G; Albeck M; Kalechman Y
J Natl Cancer Inst; 1996 Sep; 88(18):1276-84. PubMed ID: 8797767
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of the immunomodulator AS101 on B7-1 and B7-2 costimulatory molecules: role in the antitumoral effects of AS101.
Kalechman Y; Sredni B
J Immunol; 1996 Jul; 157(2):589-97. PubMed ID: 8752906
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention.
Kalechman Y; Gafter U; Gal R; Rushkin G; Yan D; Albeck M; Sredni B
J Immunol; 2002 Jul; 169(1):384-92. PubMed ID: 12077268
[TBL] [Abstract][Full Text] [Related]
4. Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop.
Sredni B; Weil M; Khomenok G; Lebenthal I; Teitz S; Mardor Y; Ram Z; Orenstein A; Kershenovich A; Michowiz S; Cohen YI; Rappaport ZH; Freidkin I; Albeck M; Longo DL; Kalechman Y
Cancer Res; 2004 Mar; 64(5):1843-52. PubMed ID: 14996748
[TBL] [Abstract][Full Text] [Related]
5. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels.
Kalechman Y; Gafter U; Da JP; Albeck M; Alarcon-Segovia D; Sredni B
J Immunol; 1997 Sep; 159(6):2658-67. PubMed ID: 9300685
[TBL] [Abstract][Full Text] [Related]
6. Immunologic effects of AS101 in the treatment of cancer patients.
Shani A; Tichler T; Catane R; Gurwith M; Rozenszajn LA; Gezin A; Levi E; Schlesinger M; Kalechman Y; Michlin H
Nat Immun Cell Growth Regul; 1990; 9(3):182-90. PubMed ID: 2370878
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation by ammonium trichloro(dioxoethylene-0,0') tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101.
Kalechman Y; Strassmann G; Albeck M; Sredni B
J Immunol; 1998 Oct; 161(7):3536-42. PubMed ID: 9759874
[TBL] [Abstract][Full Text] [Related]
8. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth.
Ghosh P; Komschlies KL; Cippitelli M; Longo DL; Subleski J; Ye J; Sica A; Young HA; Wiltrout RH; Ochoa AC
J Natl Cancer Inst; 1995 Oct; 87(19):1478-83. PubMed ID: 7674335
[TBL] [Abstract][Full Text] [Related]
9. The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma.
Kalechman Y; Shani A; Dovrat S; Whisnant JK; Mettinger K; Albeck M; Sredni B
J Immunol; 1996 Feb; 156(3):1101-9. PubMed ID: 8557985
[TBL] [Abstract][Full Text] [Related]
10. The immunomodulator AS101 restores T(H1) type of response suppressed by Babesia rodhaini in BALB/c mice.
Rosenblatt-Bin H; Kalechman Y; Vonsover A; Xu RH; Da JP; Shalit F; Huberman M; Klein A; Strassmann G; Albeck M; Sredni B
Cell Immunol; 1998 Feb; 184(1):12-25. PubMed ID: 9626331
[TBL] [Abstract][Full Text] [Related]
11. Role of endogenous cytokines secretion in radioprotection conferred by the immunomodulator ammonium trichloro(dioxyethylene-0-0')tellurate.
Kalechman Y; Zuloff A; Albeck M; Strassmann G; Sredni B
Blood; 1995 Mar; 85(6):1555-61. PubMed ID: 7888674
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional activity of a small tellurium redox immunomodulator compound, AS101, on dextran sodium sulfate-induced murine colitis.
Halpert G; Eitan T; Voronov E; Apte RN; Rath-Wolfson L; Albeck M; Kalechman Y; Sredni B
J Biol Chem; 2014 Jun; 289(24):17215-27. PubMed ID: 24764299
[TBL] [Abstract][Full Text] [Related]
13. Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice.
Kalechman Y; Rushkin G; Nerubay J; Albeck M; Sredni B
Exp Hematol; 1995 Dec; 23(13):1358-66. PubMed ID: 7498364
[TBL] [Abstract][Full Text] [Related]
14. NK cell depletion results in accelerated tumor growth and attenuates the antitumor effect of total body irradiation.
Miller GM; Andres ML; Gridley DS
Int J Oncol; 2003 Dec; 23(6):1585-92. PubMed ID: 14612930
[TBL] [Abstract][Full Text] [Related]
15. Induction of acute phase proteins in mice and humans by treatment with AS101, an immunomodulator with radioprotective properties.
Kalechman Y; Shani A; Albeck M; Sredni B
Immunopharmacology; 1995 Mar; 29(2):149-58. PubMed ID: 7539780
[TBL] [Abstract][Full Text] [Related]
16. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
[TBL] [Abstract][Full Text] [Related]
17. The effect of the novel tellurium compound AS101 on autoimmune diseases.
Halpert G; Sredni B
Autoimmun Rev; 2014 Dec; 13(12):1230-5. PubMed ID: 25153485
[TBL] [Abstract][Full Text] [Related]
18. Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101.
Frei GM; Kremer M; Hanschmann KM; Krause S; Albeck M; Sredni B; Schnierle BS
Br J Dermatol; 2008 Mar; 158(3):578-86. PubMed ID: 18241275
[TBL] [Abstract][Full Text] [Related]
19. Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2.
Wigginton JM; Lee JK; Wiltrout TA; Alvord WG; Hixon JA; Subleski J; Back TC; Wiltrout RH
J Immunol; 2002 Oct; 169(8):4467-74. PubMed ID: 12370382
[TBL] [Abstract][Full Text] [Related]
20. The immunomodulator AS101 suppresses production of inflammatory cytokines and ameliorates the pathogenesis of experimental autoimmune encephalomyelitis.
Xie L; Chen J; McMickle A; Awar N; Nady S; Sredni B; Drew PD; Yu S
J Neuroimmunol; 2014 Aug; 273(1-2):31-41. PubMed ID: 24975323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
